Advertisement
Advertisement
CSBR
Champions Oncology, Inc.
5.19
USDSponsored
0.00
0.00%
Aug 07, 15:50 UTC -4
Closed
After-Market
5.20
0.00
+0.10%
CSBR Earnings Reports
Positive Surprise Ratio
CSBR beat 18 of 33 last estimates.
55%
Next Report
Date of Next Report
Sep 14, 2026
Estimate for Q1 27 (Revenue/ EPS)
$15.35M
/-$0.01
Implied change from Q4 26 (Revenue/ EPS)
+10.88%
/-80.00%
Implied change from Q1 26 (Revenue/ EPS)
+9.65%
/-150.00%
Champions Oncology, Inc. earnings per share and revenue
On Jul 27, 2026, CSBR reported earnings of -0.05 USD per share (EPS) for Q4 26, beating the estimate of -0.05 USD, resulting in a 1.96% surprise. Revenue reached 13.84 million, compared to an expected 13.14 million, with a 5.30% difference. The market reacted with a +4.97% price change (close before vs. close after earnings).
Looking ahead to Q1 27, -- analysts forecast an EPS of -0.01 USD, with revenue projected to reach 15.35 million USD, implying an decrease of -80.00% EPS, and increase of 10.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Champions Oncology, Inc.'s earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Champions Oncology, Inc. reported EPS of -$0.05, beating estimates by 1.96%, and revenue of $13.84M, 5.3% above expectations.
How did the market react to Champions Oncology, Inc.'s Q4 2026 earnings?
The stock price moved up 4.97%, changed from $5.84 before the earnings release to $6.13 the day after.
When is Champions Oncology, Inc. expected to report next?
The next earning report is scheduled for Sep 14, 2026.
What are the forecasts for Champions Oncology, Inc.'s next earnings report?
Based on --
analysts, Champions Oncology, Inc. is expected to report EPS of -$0.01 and revenue of $15.35M for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement